Pharmacokinetics & Metabolism

How Boswellia and AKBA are absorbed, metabolised, and limited by bioavailability

Boswellia's biggest translational problem is not mechanism.

It is delivery.

Standard oral AKBA is lipophilic, poorly water-soluble, and heavily protein-bound. A high milligram label does not guarantee meaningful free systemic exposure.

Key point: a capsule labelled 180 mg AKBA does not mean 180 mg reaches blood or tissue as free active AKBA.

With standard delivery, absorption is low and albumin binding is high.

Bottom line on standard AKBA

Without an absorption strategy, standard AKBA faces four limits:

poor oral uptake
low measurable plasma exposure
very high albumin binding
first-pass and distribution losses

This is why Boswellia formulation matters much more than the headline milligram number.

What human pharmacokinetic data shows

Human work with standard Boswellia extracts shows very low systemic exposure after oral dosing.

Reported findings include:

very low or undetectable blood levels of boswellic-acid derivatives after oral use
AKBA often performing worse than some other boswellic acids in plasma exposure
a reported Cmax around 0.26 μg/mL after oral β-boswellic-acid dosing in a standard-extract setting

The practical message is simple: standard oral AKBA does not translate cleanly from capsule strength to circulating free compound.

Why absorption is poor

AKBA has several built-in pharmacokinetic disadvantages:

poor water solubility — limits dissolution in the gut
high lipophilicity — slows predictable uptake
first-pass handling — reduces systemic exposure
protein binding — reduces the free fraction after absorption

The albumin-binding problem

Low absorption is only part of the issue.

Once AKBA enters circulation, most of it binds strongly to albumin. Reviews describe protein binding above 95%.

That matters because only the free fraction is available to interact with targets.

In mechanistic work, albumin has been shown to abolish the 5-LOX inhibitory effect of boswellic acids in whole-blood-style conditions. That helps explain why promising cell and enzyme data often weakens in vivo.

The concentration gap in oncology

Many cell-culture oncology papers use AKBA concentrations that are far above the plasma levels reported with standard oral extracts.

Standard oral studies tend to report plasma exposure in the sub-μg/mL range.

After protein binding, the free fraction is smaller still.

That does not make the laboratory data useless.

It does mean a standard capsule even with claims of 90% AKBA is unlikely to reproduce anything remotely close to those tissue conditions on label strength alone.

Why the label can overstate the real dose

A 200mg capsule (standard e.g is not labelled liposomal) with a 90% AKBA claim is saying we are selling you 180 mg AKBA capsule.

Research clearly indicates with standard 180mg oral AKBA

Peak plasma: ~0.26-0.5 μg/mL (optimistically)
Free (unbound) AKBA: <5% of that = 0.01-0.025 μg/mL
This is 200-2000x BELOW the therapeutic concentration needed

What improves the picture

The main ways to improve real-world exposure are:

use enhanced-delivery systems such as liposomal
judge products by AKBA content plus delivery design, not AKBA content alone

For dose context, see Dosing & Timing.

For product-comparison logic, see Sourcing Quality Boswellia.

Research clearly shows that standard AKBA without enhanced delivery has only ~1-2% bioavailability .

This means a non-liposomal 200mg capsule with 90% AKBA actually delivers approximately 2.7 mg of absorbed AKBA to the bloodstream, not 180 mg.

The MCS Formulas Boswellia MEGA AKBA (a 200mg capsule which contains 60mg AKBA at 30% standardization) uses liposomal delivery technology + BioPerine. Published research shows this combination improves bioavailability by approximately 5-fold.

That means it delivers approximately 4.7 mg of bioavailable AKBA—making it actually 1.7x stronger than the standard (non-liposomal) products, despite having a lower number on the label.

For cancer patients trying to achieve therapeutic tissue concentrations (5-20 μg/mL needed for anticancer effects based on in vitro studies), this distinction is critical. We simply can't assess 'strength' by label claims alone—we have to look at what actually gets absorbed.

For oncology dosing at therapeutic levels:

One example is a standard 200mg capsule claiming 90% AKBA providing at 2.7 mg bioavailable per capsule: Insufficient even at multiple caps/day. To potentially reach therapeutic levels would require 6-7+ capsules daily = Approx US$8-9/day + delivery

MCS MEGA AKBA at 4.7 mg bioavailable: Would need 3-4 capsules/day = US $2.34-3.12/day

MCS Inflasanum (perscription only) at 8.5 mg bioavailable: Potentially therapeutic at just 1-2 capsules/day = $1.48-2.96/day

So when we look at the actual daily cost to reach therapeutic dosing, a standad non-liposomal supplement even with 90% AKBA on the label becomes 3-6x more expensive than the MCS Formulas products, while delivering questionable bioavailability.

MCS Formulas has specialized in creating formulas specifically for the cancer community, taking on the bioavailability and purity challenges from day one. Their products use third-party testing (Eurofins, Agrolab) and enhanced delivery systems.

I know this seems counterintuitive because we're used to comparing label numbers, but for our community members who are investing their limited resources into supplements hoping for therapeutic benefit, understanding bioavailability is essential. A high number on the label means nothing if it doesn't get absorbed.

See Boswellia Sourcing and Dosing and Trusted Supplier page for more details

CYP interactions

Boswellia has in vitro relevance for:

CYP1A2
CYP2C9
CYP2C19
CYP2D6
CYP3A4

This matters for oncology drugs such as taxanes, tamoxifen-related metabolism, corticosteroids, and other supportive medications.

Brain access relevance

Boswellia's clinical activity in cerebral oedema supports meaningful CNS relevance even if standard pharmacokinetic modelling remains incomplete.

That signal is clinically important, but it should not be confused with proof of strong systemic AKBA exposure from every standard oral product.

Key references

Enhanced Bioavailability of Boswellic Acid by Piper longum
https://pmc.ncbi.nlm.nih.gov/articles/PMC7770183/

Pharmacokinetic study of 11-keto-β-boswellic acid
https://www.sciencedirect.com/science/article/pii/S0367326X1200278X

Anti-cancer properties of boswellic acids: mechanism of action as an anti-cancerous agent
https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2023.1187181/full

An Update on Pharmacological Potential of Boswellic Acids in Cancer
https://pmc.ncbi.nlm.nih.gov/articles/PMC6747466/

Novel pharmacological strategies to improve boswellic acid delivery and activity
https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1692443/full

Jump to another Boswellia page

Core pages

Mechanism deep dives

Practical pages

Cancer-type pages

This information is for education only. It is not medical advice, diagnosis, or treatment. Please speak with a qualified clinician before making changes to care, medication, or supplement use.